Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team

Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbi...

Source: Orphanet Journal of Rare Diseases - October 7, 2023 Category: Internal Medicine Authors: Colleen McCabe, Hillary Wright, Kathleen Polson and Andrew J. Wagner Tags: Position statement Source Type: research